Literature DB >> 12452621

The effects of GnRH analogues and antiandrogenes in preventing the gonadotoxic effects of COPP chemotherapy.

M Göçmen1, A F Akay, H Sahin, M Deniz, Y Nergiz, M K Bircan.   

Abstract

BACKGROUND: In this study we aimed to discuss whether the gonadal suppression is effective or not in preventing the gonadal toxic effects of some chemotherapeutics.
METHODS: Forty Sprague-Dawley adult male rats were randomised into 4 groups, each consisting of 10. No drugs were given to the first group. The second group received GnRH agonist and antiandrogen, the third group received COPP chemotherapy protocol and the last group received COPP together with GnRH agonist and antiandrogen. Ninety days after drug application we sacrificed all rats. Total body weight, testicular weight and testicular size measurements were all recorded. All testicular tissues were examined histologically for the ratio of active seminiferous tubules.
RESULTS: There was no difference in total body weight. The weight and measurements of testicular tissues were decreased in-group 3 and 4 when compared with 1 and 2. The amount of active seminiferous tubules was significantly less in the third group.
CONCLUSIONS: As a conclusion we think that gonadal suppression applied during chemotherapy regimen could decrease the testicular toxic effects of chemotherapeutic but more clinical investigations needed for routine application.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12452621     DOI: 10.1023/a:1020518916072

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  11 in total

1.  Radiation survival and regeneration characteristics of spermatogenic stem cells of mouse testis.

Authors:  H R Withers; N Hunter; H T Barkley; B O Reid
Journal:  Radiat Res       Date:  1974-01       Impact factor: 2.841

2.  Protection from procarbazine-induced damage of spermatogenesis in the rat by androgen.

Authors:  J I Delic; C Bush; M J Peckham
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

3.  Treatment with the gonadotropin-releasinghormone agonist buserelin to protect spermatogenesis against cytotoxic treatment in young men.

Authors:  W Krause; K H Pflüger
Journal:  Andrologia       Date:  1989 May-Jun       Impact factor: 2.775

4.  Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.

Authors:  J A Ward; J Robinson; B J Furr; S M Shalet; I D Morris
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

5.  Failure to preserve fertility in patients with Hodgkin's disease.

Authors:  J H Waxman; R Ahmed; D Smith; P F Wrigley; W Gregory; S Shalet; D Crowther; L H Rees; G M Besser; J S Malpas
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].

Authors:  W Kuber; T Treu; C Kratzik; E Girsch; R Zeillinger; J Spona
Journal:  Wien Klin Wochenschr       Date:  1990-11-09       Impact factor: 1.704

7.  Does a gonadotropin-releasing hormone analogue prevent cisplatin-induced spermatogenic impairment? An experimental study in the mouse.

Authors:  M Nonomura; K Okada; S Hida; O Yoshida
Journal:  Urol Res       Date:  1991

8.  D-Tryptophan-6 analog of luteinizing hormone-releasing hormone as a protective agent against testicular damage caused by cyclophosphamide in baboons.

Authors:  R W Lewis; K J Dowling; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

9.  Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations.

Authors:  D H Johnson; R Linde; J D Hainsworth; W Vale; J Rivier; R Stein; J Flexner; R Van Welch; F A Greco
Journal:  Blood       Date:  1985-04       Impact factor: 22.113

10.  Protection of the germinal epithelium in the rat from the cytotoxic effects of chemotherapy by a luteinizing hormone-releasing hormone agonist and antiandrogen therapy.

Authors:  R D Cespedes; S J Peretsman; I M Thompson; C Jackson
Journal:  Urology       Date:  1995-11       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.